Sanli Yasemin, Sanli Oner, Has Simsek Duygu, Subramaniam Rathan M
Department of Radiology, Division of Nuclear Medicine.
Departments of Urology.
Nucl Med Commun. 2018 Oct;39(10):871-880. doi: 10.1097/MNM.0000000000000888.
Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa.
高危前列腺癌（HRPCa）的治疗具有挑战性。局部分期和转移评估对患者管理很重要。最近，基于前列腺特异性膜抗原（PSMA）的成像方式，如PSMA PET/CT和PET/MRI，在检测治疗后前列腺特异性抗原水平升高的复发性前列腺癌部位方面受到了极大关注。目前的证据表明，这些成像方式在HRPCa患者的管理中可能也发挥作用。在这篇综述中，我们讨论基于PSMA的成像方式在HRPCa患者管理中的应用。
